Protas has been established to fix the market failure which drives the declining development of treatments for common diseases. Our goal is to reduce barriers in the development of better treatments for common diseases and improve public health outcomes by combining smart randomized trial design with effective technology and collaborative partnerships. Put simply – delivering smarter trials for better health.
We will build on the experience of the world-leading Oxford Clinical Trial Service Unit (CTSU) at Oxford University and the landmark clinical trials it has conducted. This includes the RECOVERY trial of treatments for COVID-19, which, amongst other things, discovered that dexamethasone, a low-cost and common steroid, would lower the risk of dying from Covid-19 by a third, saving hundreds of thousands of lives around the world. Other landmark trials include the Heart Protection Study trial of statins, ISIS trials of treatments for acute myocardial infarction, and SHARP trial of cholesterol-lowering in chronic kidney disease.
We will radically readjust the economics of late-stage randomized clinical trials. By designing and delivering these smarter trials at a fraction of the current industry cost, we will encourage more trials for treatments of commons diseases, which would have profound implications for health of nations and the health systems that support them.
More information what we are can be found on the ‘What we do’ page.
“A New National Purpose”: Protas named in report on innovation
Protas was this week named in a new report exploring how the UK should harness innovation in science and technology…
Protas signs strategic partnership with Moderna
Protas is delighted to announce a new strategic partnership with Moderna, the leading biotechnology company pioneering messenger RNA (mRNA). Moderna’s…